FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 1197 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Strangers Buy Boy Stuffed Animals For His Birthday When His Mom... August 25, 2021 Nivolumab Plus Low-Dose Ipilimumab Demonstrates Clinical Benefit in First-Line Treatment for... October 20, 2021 Adjuvant Nivolumab Plus Ipilimumab Combination Does Not Improve RFS Over Nivolumab... October 4, 2022 NICE doesn’t recommend ibrutinib drug for those with Waldenstrom’s macroglobulinaemia May 23, 2022 Load more HOT NEWS From Scan to Scan: The Challenges of Living with Metastatic Cancer After A Long And Dangerous Battle, Africa Has Been Declared Free... A winding journey into the world of children’s and young people’s... Spotlight On: Pelvic Physical Therapists in Cancer Care
